JPRN-UMIN000003496RecruitingPhase 2
Multicenter Phase II study of TS-1 and gemcitabine combination therapy for elderly patients with unresectable pancreatic cancer. - TS-1/gemcitabine regimen in elderly patients with pancreatic cancer.
Ochanomizu Gastrointestinal Oncology Group0 sites30 target enrollmentStarted: April 15, 2010Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Sponsor
- Enrollment
- 30
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 70years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1) Pulmonary fibrosis or interstitial pneumonia 2) Active double cancer, or history of cancer unless it was surgically removed intraepithrial cancer or is considered to be cured with no less that 10 years of recurrence-free 3) Severe complications, such as (1)poorly controlled diabetes melitus and hypertension (2)poorly controlled angina pectoris, heart failure, or myocardial infarction (3)active infection (4)other diseases with inadequate physical condition, such as ileus, bleeding tendency and diarrhea 4) Symptomatic metastasis in central nervous system 5) Severe mental disorders 6) History of drug hypersensitivity
Investigators
Similar Trials
Completed
Phase 2
A phase II study of gemcitabine and TS-1 in erderly patients with advanced non-small cell lung cancerAdvanced non-small cell lung cancerJPRN-UMIN000001750Gunma University Hospital40
Completed
Phase 2
Multicenter phase II trial of gemcitabine and S-1 for gallbladder cancergallbladder cancerJPRN-UMIN000001267agoya University Hospital20
Completed
Phase 2
Randomized phase II study comparing Gemcitabine/TS-1 combination chemoradiotherapy with Gemcitabine/TS-1 combination chemotherapy for unresectable locally advanced pancreatic cancer.nresectable locally advanced pancreatic cancer.JPRN-UMIN000001990Osaka Medical Center for Cancer and Cardiovascular Diseases Department of Medical Oncology110
Recruiting
Phase 1
Phase I/II study of Gemcitabine and S-1 (GS therapy) as Neoadjuvant chemoradiationtherapy for borderline resectable pancreatic cancer (Prep-03/NS014-1)Borderline resectable pancreatic cancerJPRN-UMIN000014498Study group of preoperative therapy for pancreatic cancer (PREP)40
Recruiting
Phase 1
Prep-03C535836Pancreatic cancerpancreatic cancerJPRN-jRCTs021180045nno Michiaki40